Table 2.
Medical and obstetric complications.
|
Literature review and CHUM cohort (63 W, 80 P) |
CHUM cohort only(10 W, 12 P) |
|||
|---|---|---|---|---|
| P/N | % | P/N | % | |
| Medical complications | ||||
| Relapse | 16/60 | 26.7 | 0/11 | 0 |
| PAHa | 7/80 | 8.8 | 1/12 | 8.3 |
| ILDa | 11/80 | 13.8 | 2/12 | 16.6 |
| Non-preeclamptic proteinuriaa | 11/80 | 13.8 | 0/12 | 0 |
| SRCa | 1/80 | 1.3 | 0/12 | 0 |
| Obstetric complications | ||||
| Preeclampsia | 13/74 | 17.6 | 3/11 | 27.2 |
| Caesarean section | 19/61 | 31.1 | 3/11 | 27.2 |
| VTE | 2/80 | 2.5 | 0/12 | 0 |
| Maternal mortality | 2/80 | 2.5 | 0/12 | 0 |
| Prematurity | 25/52 | 48.1 | 2/11 | 18.2 |
| IUGR | 19/49 | 38.8 | 2/11 | 18.2 |
| NL | 6/63 | 9.5 | 0/9 | 0 |
| CP | 13/63 | 20.6 | 0/9 | 0 |
| Perinatal mortalityb | 14/79 | 17.7 | 0/12 | 0 |
CP: chondrodysplasia punctata; ILD: interstitial lung disease; IUGR: intrauterine growth restriction; N: available sample size per category; NL: neonatal lupus; PAH: pulmonary arterial hypertension; P: pregnancy; SRC: scleroderma renal crisis; VTE: venous thromboembolism; W: women.
aPrevalence based on total cohort as no systematic screening was made.
bFetus and neonates combined.